SCHEMBL7344446

SCHEMBL7344446

COC(=O)COc1ccc2cc(C(=N)N)ccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 11/20 0.54
PLG P00747 7/20 0.51
F2 P00734 8/20 0.49
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
FTO Q9C0B1 1/20 0.47
POLB P06746 1/20 0.47
PRSS1 P07477 6/20 0.47
KLKB1 P03952 5/20 0.47
KLK1 P06870 3/20 0.47
PLAT P00750 3/20 0.47
TMPRSS2 O15393 1/20 0.47
MLNR O43193 1/20 0.47
C1R P00736 1/20 0.47
F10 P00742 1/20 0.47
F12 P00748 1/20 0.47
LMNA P02545 1/20 0.47
ITGB3 P05106 1/20 0.47
HPN P05981 1/20 0.47
CHRM2 P08172 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7341713 0.86 PLAU (0.65) PLAUPLGF2ALDH1A1PRSS1
SCHEMBL10080489 0.84 KDM4E (0.63) ALDH1A1KDM4EPTGS2
SCHEMBL6288707 0.84 MAPT (0.51) ALDH1A1KDM4EPOLBLMNAMAPT
SCHEMBL7336793 0.84 PTPN7 (0.61) PLAUPLGF2ALDH1A1PRSS1
SCHEMBL8409575 0.82 PRSS1 (0.54) PLAUPLGF2POLBPRSS1
SCHEMBL8407192 0.82 PRSS1 (0.54) PLAUPLGF2POLBPRSS1
SCHEMBL7341318 0.82 PDE3B (0.49) PLAUPLGF2PRSS1TMPRSS2
SCHEMBL7283709 0.80 ITGB3 (0.52) F2ALDH1A1POLBPRSS1TMPRSS2
Trifluoroacetic Acid SCHEMBL7335972 0.80 PLAU (0.56) PLAUPLGF2PRSS1KLKB1
SCHEMBL7347409 0.80 PLAU (0.52) PLAUPLGF2ALDH1A1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP claimed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885PLG 10/4885F2 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.